Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)

NCT06075264 is registered in ClinicalTrials.gov with Frantz Viral Therapeutics, LLC as lead sponsor.

NCT NCT06075264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06075264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)
Lead sponsor
Frantz Viral Therapeutics, LLC
Phase
Phase 2
Overall status
Recruiting
Start date
December 6, 2023
Completion date
December 31, 2027
Enrollment
27 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

high grade intraepithelial neoplasia, hpv disease, hpv infection, pre-cancerous dysplasia, vin 2 of usual type, vin 3 of usual type, vin grade 2, vin grade 3, vin ii, vin iii, vin, usual type, vulvar diseases, vulvar hsil